Received Sep 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | — | — |
No additional AE reported.; patient received her first dose of GARDASIL 9 on 03SEP2014 "when she was 13 years old", she received her second dose on 20AUG2018 and her third dose on 26JUN2025 and is now 24 years old; This spontaneous report was received from a Nurse and refers to a 24-year-old female patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 03-Sep-2014, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), dose number 1, (dose 1), (lot # and expiration date were not reported); On 20-Aug-2018, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), dose number 2, (dose 2), (lot # and expiration date were not reported) and finally, on 26-Jun-2025, with the third dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), dose number 3, (dose 3), (lot # and expiration date were not reported). All the doses administered as prophylaxis. The reporting nurse called and reported that there was a patient that wanted to know if she needed any additional doses of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) or if the series needed to be restarted. Because the patient received her first dose "when she was 13 years old" and she received her third dose now at 24 years old. No additional adverse events were reported.